Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

ABSTRACT During the last several years a series of staphylococcal isolates that demonstrated reduced susceptibility to vancomycin or other glycopeptides have been reported. We selected 12 isolates of staphylococci for which the vancomycin MICs were ≥4 μg/ml or for which the teicoplanin MICs were ≥8 μg/ml and 24 control strains for which the vancomycin MICs were ≤2 μg/ml or for which the teicoplanin MICs were ≤4 μg/ml to determine the ability of commercial susceptibility testing procedures and vancomycin agar screening methods to detect isolates with reduced glycopeptide susceptibility. By PCR analysis, none of the isolates with decreased glycopeptide susceptibility contained known vancomycin resistance genes. Broth microdilution tests held a full 24 h were best at detecting strains with reduced glycopeptide susceptibility. Disk diffusion did not differentiate the strains inhibited by 8 μg of vancomycin per ml from more susceptible isolates. Most of the isolates with reduced glycopeptide susceptibility were recognized by MicroScan conventional panels and Etest vancomycin strips. Sensititre panels read visually were more variable, although with some of the panels MICs of 8 μg/ml were noted for these isolates. Vitek results were 4 μg/ml for all strains for which the vancomycin MICs were ≥4 μg/ml. Vancomycin MICs on Rapid MicroScan panels were not predictive, giving MICs of either ≤2 or ≥16 μg/ml for these isolates. Commercial brain heart infusion vancomycin agar screening plates containing 6 μg of vancomycin per ml consistently differentiated those strains inhibited by 8 μg/ml from more susceptible strains. Vancomycin-containing media prepared in-house showed occasional growth of susceptible strains, Staphylococcus aureus ATCC 29213, and on occasion, Enterococcus faecalis ATCC 29212. Thus, strains of staphylococci with reduced susceptibility to glycopeptides, such as vancomycin, are best detected in the laboratory by nonautomated quantitative tests incubated for a full 24 h. Furthermore, it appears that commercial vancomycin agar screening plates can be used to detect these isolates.

[1]  H. Narita,et al.  Characteristics of quinolone-induced small colony variants in Staphylococcus aureus. , 1997, The Journal of antimicrobial chemotherapy.

[2]  C. O'callaghan,et al.  Novel Method for Detection of β-Lactamases by Using a Chromogenic Cephalosporin Substrate , 1972, Antimicrobial Agents and Chemotherapy.

[3]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[4]  J. Duval,et al.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. , 1988, The New England journal of medicine.

[5]  J. Miller,et al.  Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus , 1995, Journal of clinical microbiology.

[6]  F. Aarestrup,et al.  Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster , 1996, Antimicrobial agents and chemotherapy.

[7]  A. C. McIntosh,et al.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci , 1996, Antimicrobial agents and chemotherapy.

[8]  R N Jones,et al.  Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. , 1995, Diagnostic microbiology and infectious disease.

[9]  G. Wormser,et al.  Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit , 1994, Antimicrobial Agents and Chemotherapy.

[10]  N. Woodford,et al.  VANCOMYCIN-RESISTANT ENTEROCOCCI , 1988, The Lancet.

[11]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[12]  M. Weinstein,et al.  Development of a standardized screening method for detection of vancomycin-resistant enterococci , 1994, Journal of clinical microbiology.

[13]  Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996. , 1997, MMWR. Morbidity and mortality weekly report.

[14]  Elaine Larson,et al.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[15]  Centersfordiseasecontrolandpr Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. , 1997, MMWR. Morbidity and mortality weekly report.

[16]  H. Goossens,et al.  Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients , 1995, Journal of clinical microbiology.

[17]  V. Yu,et al.  In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis , 1996, Antimicrobial agents and chemotherapy.

[18]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[19]  J. Morris,et al.  Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin: Establishment of Endemicity in a University Medical Center , 1995, Annals of Internal Medicine.

[20]  R. Daum,et al.  Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus , 1997, Antimicrobial agents and chemotherapy.

[21]  A. Tomasz,et al.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus , 1997, Journal of bacteriology.

[22]  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[23]  D. Williams,et al.  The structure and mode of action of glycopeptide antibiotics of the vancomycin group. , 1984, Annual review of microbiology.

[24]  C. Stratton,et al.  RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. , 1993, Diagnostic microbiology and infectious disease.

[25]  F. Tenover,et al.  Characterization of glycopeptide-resistant enterococci from U.S. hospitals , 1993, Antimicrobial Agents and Chemotherapy.

[26]  M. Weinstein,et al.  Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci , 1995, Journal of clinical microbiology.

[27]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[28]  Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. , 1993, MMWR. Morbidity and mortality weekly report.

[29]  F. Tenover,et al.  Detection and Differentiation of vanC-1,vanC-2, and vanC-3 Glycopeptide Resistance Genes in Enterococci , 1998, Journal of Clinical Microbiology.

[30]  F. Tenover,et al.  Detection of vancomycin-resistant enterococci in fecal samples by PCR , 1997, Journal of clinical microbiology.

[31]  S. Gupta,et al.  Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. , 1992, The Journal of infectious diseases.

[32]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[33]  W. Noble,et al.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. , 1992, FEMS microbiology letters.

[34]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.